WC
JSPR icon

Wealthspring Capital’s Jasper Therapeutics JSPR Stock Holding History

Wealthspring Capital’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,327
Closed -$430K – 316
2021
Q2 		$430K Hold
4,327
– – 0.11% 219
2021
Q1 		$429K Hold
4,327
– – 0.12% 201
2020
Q4 		$433K Buy
+4,327
New +$431K 0.21% 119

Other funds holding JSPR

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LPARFS
Leverage Partners Absolute Return Fund SPC Cayman Islands Ky1-11111, Cayman Islands $54K AUM
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Wealthspring Capital's JSPR Position: Q3 2021 in Review

Wealthspring Capital sold out of Jasper Therapeutics (JSPR) in Q3 2021, closing a stake of 4,327 shares — an estimated $430K sold.

Wealthspring Capital first reported a position in JSPR in Q4 2020 and held it in 3 quarters. The position peaked at $433K in Q4 2020. 10 funds tracked by Wall St. Rank hold JSPR as of Q3 2021.

  • Wealthspring Capital reported no remaining Jasper Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Wealthspring Capital sold 4,327 Jasper Therapeutics shares in Q3 2021, an estimated $430K.
  • Wealthspring Capital first reported a position in Jasper Therapeutics in Q4 2020 and held it in 3 quarters.
  • Wealthspring Capital's Jasper Therapeutics position peaked at $433K in Q4 2020.
  • 10 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q3 2021.

Based on Wealthspring Capital's 13F filing for Q3 2021, filed 2 Nov 2021.